Business
Change of Adviser
Change of Adviser.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 6677A Physiomics PLC 31 May 2019 \n\n31 May 2019\n \nPhysiomics plc\n(\"Physiomics\") or (the \"Company\")\n \nChange of Adviser\n \nPhysiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has appointed Strand Hanson Limited as its Nominated and Financial Adviser, with immediate effect.\n \nHybridan LLP will continue to act as the Company's sole broker.\n \nEnquiries:\n \nPhysiomics plc\nDr Jim Millen, CEO\n+44 (0)1865 784 980\n \nStrand Hanson Ltd (NOMAD)\nRichard Tulloch & James Dance\n+44 (0) 20 7409 3494\n \nHybridan LLP (Broker)\nClaire Louise Noyce\n+44 (0) 20 3764 2341\n \nNotes to Editor\n \nAbout Physiomics\n \nPhysiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.\n \nBased in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight. \n \nPhysiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END APPURRNRKVAVOAR\n ","length":3651...